CERO — CERo Therapeutics Holdings Share News
0.000.00%
Last trade - 00:00Brief: Cero Therapeutics Announces Critical Patent Application Allowances From The U.S. Patent Office
Brief: Cero Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
Brief: Cero Therapeutics Holdings Announces Reverse Stock Split
Brief: CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO
Brief: Cero Therapeutics Holdings fails to regain compliance with Nasdaq MVLS requirement
Brief: Cero Therapeutics, Inc. Provides Corporate Update
Brief: CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236
Brief: Cero Therapeutics Holdings Inc Charles R. Carter To Serve As The Chief Financial Officer Until September 30
Brief: CERo Therapeutics Says Co Informed FDA Placed Clinical Hold On Its Investigational New Drug Application Of CER-1236
Brief: CERo Therapeutics Files Prospectus Relates To Potential Offer Of Up To 25.6 Mln Common Shares
U.S. STOCKS ON THE MOVE-Hyatt, Fortrea, China ADRs
Brief: Cero Therapeutics Holdings Enters Into Purchase Agreement With Arena Business Solutions Global
Brief: Phoenix Biotech Acquisition And Cero Therapeutics Announce Close Of Business Combination
Brief: Phoenix Biotech Acquisition Corp Says Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Brief: Cero Therapeutics And Phoenix Biotech Announce Merger Agreement
Brief: Phoenix Biotech Acquisition Corp Says On April 3, Got Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Brief: Intrinsic Medicine And Phoenix Biotech Acquisition Mutually Agree To Terminate Business Combination Agreement
Brief: Intrinsic And Phoenix Biotech Announce Merger Agreement
Brief: Phoenix Biotech Acquisition Corp. Announces Pricing Of $155,000,000 Initial Public Offering